DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice

M. Mkrtichyan, A. Ghochikyan, D. Loukinov, H. Davtyan, T. E. Ichim, D. H. Cribbs, V. V. Lobanenkov, M. G. Agadjanyan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immunogenicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this molecule (mBORIS) that lacks tumorigenic ability, while retaining immunogenic epitopes that elicits responses against histologically irrelevant tumor cells. Here we compared vaccine strategies employing as an immunogen either mBORIS recombinant protein formulated in a strong Th1-type adjuvant, QuilA or DNA encoding this immunogen along with plasmids expressing interleukin (IL)12/IL18 molecular adjuvants. In both groups of vaccinated mice induction of tumor-specific immunity (antibody response, T-cell proliferation, cytokine production, T-cell cytotoxicity) as well as ability to inhibit growth of the aggressive breast cancer cell line and to prolong survival of vaccinated animals have been tested. We determined that DNA, but not recombinant protein vaccine, induced potent Th1-like T-cell recall responses that significantly inhibited tumor growth and prolongs the survival of vaccinated mice. These studies demonstrate that DNA immunization is superior to recombinant protein strategy and provide a clear guidance for clinical development of a cancer vaccine targeting what appears to be a universal tumor antigen.

Original languageEnglish (US)
Pages (from-to)61-64
Number of pages4
JournalGene Therapy
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Vaccines
Antigens
DNA
Growth
Cancer Vaccines
Neoplasms
Proteins
T-Lymphocytes
Recombinant Proteins
Synthetic Vaccines
Interleukin-18
Neoplasm Antigens
Interleukin-12
Antibody Formation
Epitopes
Immunity
Immunization
Plasmids
Transcription Factors
Cell Proliferation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Mkrtichyan, M., Ghochikyan, A., Loukinov, D., Davtyan, H., Ichim, T. E., Cribbs, D. H., ... Agadjanyan, M. G. (2008). DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Therapy, 15(1), 61-64. https://doi.org/10.1038/sj.gt.3303044

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. / Mkrtichyan, M.; Ghochikyan, A.; Loukinov, D.; Davtyan, H.; Ichim, T. E.; Cribbs, D. H.; Lobanenkov, V. V.; Agadjanyan, M. G.

In: Gene Therapy, Vol. 15, No. 1, 01.01.2008, p. 61-64.

Research output: Contribution to journalArticle

Mkrtichyan, M, Ghochikyan, A, Loukinov, D, Davtyan, H, Ichim, TE, Cribbs, DH, Lobanenkov, VV & Agadjanyan, MG 2008, 'DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice', Gene Therapy, vol. 15, no. 1, pp. 61-64. https://doi.org/10.1038/sj.gt.3303044
Mkrtichyan, M. ; Ghochikyan, A. ; Loukinov, D. ; Davtyan, H. ; Ichim, T. E. ; Cribbs, D. H. ; Lobanenkov, V. V. ; Agadjanyan, M. G. / DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. In: Gene Therapy. 2008 ; Vol. 15, No. 1. pp. 61-64.
@article{999b0eb3e53a482298ac292d79d1b8ee,
title = "DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice",
abstract = "The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immunogenicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this molecule (mBORIS) that lacks tumorigenic ability, while retaining immunogenic epitopes that elicits responses against histologically irrelevant tumor cells. Here we compared vaccine strategies employing as an immunogen either mBORIS recombinant protein formulated in a strong Th1-type adjuvant, QuilA or DNA encoding this immunogen along with plasmids expressing interleukin (IL)12/IL18 molecular adjuvants. In both groups of vaccinated mice induction of tumor-specific immunity (antibody response, T-cell proliferation, cytokine production, T-cell cytotoxicity) as well as ability to inhibit growth of the aggressive breast cancer cell line and to prolong survival of vaccinated animals have been tested. We determined that DNA, but not recombinant protein vaccine, induced potent Th1-like T-cell recall responses that significantly inhibited tumor growth and prolongs the survival of vaccinated mice. These studies demonstrate that DNA immunization is superior to recombinant protein strategy and provide a clear guidance for clinical development of a cancer vaccine targeting what appears to be a universal tumor antigen.",
author = "M. Mkrtichyan and A. Ghochikyan and D. Loukinov and H. Davtyan and Ichim, {T. E.} and Cribbs, {D. H.} and Lobanenkov, {V. V.} and Agadjanyan, {M. G.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1038/sj.gt.3303044",
language = "English (US)",
volume = "15",
pages = "61--64",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice

AU - Mkrtichyan, M.

AU - Ghochikyan, A.

AU - Loukinov, D.

AU - Davtyan, H.

AU - Ichim, T. E.

AU - Cribbs, D. H.

AU - Lobanenkov, V. V.

AU - Agadjanyan, M. G.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immunogenicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this molecule (mBORIS) that lacks tumorigenic ability, while retaining immunogenic epitopes that elicits responses against histologically irrelevant tumor cells. Here we compared vaccine strategies employing as an immunogen either mBORIS recombinant protein formulated in a strong Th1-type adjuvant, QuilA or DNA encoding this immunogen along with plasmids expressing interleukin (IL)12/IL18 molecular adjuvants. In both groups of vaccinated mice induction of tumor-specific immunity (antibody response, T-cell proliferation, cytokine production, T-cell cytotoxicity) as well as ability to inhibit growth of the aggressive breast cancer cell line and to prolong survival of vaccinated animals have been tested. We determined that DNA, but not recombinant protein vaccine, induced potent Th1-like T-cell recall responses that significantly inhibited tumor growth and prolongs the survival of vaccinated mice. These studies demonstrate that DNA immunization is superior to recombinant protein strategy and provide a clear guidance for clinical development of a cancer vaccine targeting what appears to be a universal tumor antigen.

AB - The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immunogenicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this molecule (mBORIS) that lacks tumorigenic ability, while retaining immunogenic epitopes that elicits responses against histologically irrelevant tumor cells. Here we compared vaccine strategies employing as an immunogen either mBORIS recombinant protein formulated in a strong Th1-type adjuvant, QuilA or DNA encoding this immunogen along with plasmids expressing interleukin (IL)12/IL18 molecular adjuvants. In both groups of vaccinated mice induction of tumor-specific immunity (antibody response, T-cell proliferation, cytokine production, T-cell cytotoxicity) as well as ability to inhibit growth of the aggressive breast cancer cell line and to prolong survival of vaccinated animals have been tested. We determined that DNA, but not recombinant protein vaccine, induced potent Th1-like T-cell recall responses that significantly inhibited tumor growth and prolongs the survival of vaccinated mice. These studies demonstrate that DNA immunization is superior to recombinant protein strategy and provide a clear guidance for clinical development of a cancer vaccine targeting what appears to be a universal tumor antigen.

UR - http://www.scopus.com/inward/record.url?scp=37249076017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249076017&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3303044

DO - 10.1038/sj.gt.3303044

M3 - Article

C2 - 17972923

AN - SCOPUS:37249076017

VL - 15

SP - 61

EP - 64

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 1

ER -